Gene · 81607
Papers1,879
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,879
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical application and optimization strategies for antibody-drug conjugates in solid tumors. | J Int Med Res | 2026 | 41904967 | PubTator, text mining | PubMed |
| Receptor-Mediated Drug Delivery: Redefining Targeted Drug Conjugates in Oncology. | Pharmaceutics | 2026 | 41900872 | PubTator, text mining | PubMed |
| New Frontiers in the Pathophysiology of Hypertensive Pregnancy Disorders: A Systematic Review of Molecular Insights into Preeclampsia. | Curr Issues Mol Biol | 2026 | 41899446 | PubTator, text mining | PubMed |
| Decreasing Antibody Titers and the Slow Decay of Measles Immunity in Mexico's Current Epidemiological Landscape. | Vaccines (Basel) | 2026 | 41893771 | PubTator, text mining | PubMed |
| Urothelial Carcinoma of the Bladder with a Single Pancreatic Metastasis: A Case Report. | Reports (MDPI) | 2026 | 41893442 | PubTator, text mining | PubMed |
| Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer. | Curr Oncol | 2026 | 41892190 | PubTator, text mining | PubMed |
| Nectin-4 expression in vulvar squamous cell carcinoma. | Virchows Arch | 2026 | 41888429 | PubTator, text mining | PubMed |
| Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation. | J Int Med Res | 2026 | 41885091 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in prostate cancer: current landscape and future directions. | Ther Adv Med Oncol | 2026 | 41883865 | PubTator, text mining | PubMed |
| Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). | Cancer Immunol Immunother | 2026 | 41874648 | PubTator, text mining | PubMed |
| The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents. | Curr Opin Urol | 2026 | 41861349 | PubTator, text mining | PubMed |
| Novel radiopharmaceuticals for bladder cancer evaluation. | Q J Nucl Med Mol Imaging | 2026 | 41854639 | PubTator, text mining | PubMed |
| Spatial heterogeneity of antibody-drug conjugate targets in pancreatic ductal adenocarcinoma. | J Pathol Clin Res | 2026 | 41837391 | PubTator, text mining | PubMed |
| Personalised medicine in urothelial carcinoma: where do we stand and what is the way to go? | Curr Opin Urol | 2026 | 41827087 | PubTator, text mining | PubMed |
| The rationale for targeting nectin-4 in pancreatic cancer. | Trends Cancer | 2026 | 41813473 | PubTator, text mining | PubMed |
| Expression characteristics of clinically relevant antibody-drug conjugate targets in gestational trophoblastic neoplasia. | Hum Pathol | 2026 | 41812828 | PubTator, text mining | PubMed |
| Clinical application prospects of Nectin-4 in pan-cancer: an analysis based on the Trialtrove database. | J Immunother Cancer | 2026 | 41807035 | PubTator, text mining | PubMed |
| Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. | Clin Transl Med | 2026 | 41804750 | PubTator, text mining | PubMed |
| 68Ga/177Lu-labeled nectin4-targeted covalent bicyclic peptide: a novel nectin-4-targeted radioligands for theranostic of urothelial carcinoma. | J Nanobiotechnology | 2026 | 41794719 | PubTator, text mining | PubMed |
| Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer. | Front Immunol | 2026 | 41789080 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/81607/papers?page=6